Mereo BioPharma Group (Mereo BioPharma Group) Long-Term Debt : $4.39 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Long-Term Debt?

Mereo BioPharma Group's Long-Term Debt for the quarter that ended in Dec. 2023 was $4.39 Mil.

Mereo BioPharma Group's quarterly Long-Term Debt increased from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($4.62 Mil) but then declined from Jun. 2023 ($4.62 Mil) to Dec. 2023 ($4.39 Mil).

Mereo BioPharma Group's annual Long-Term Debt declined from Dec. 2021 ($19.41 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($4.39 Mil).

Mereo BioPharma Group Long-Term Debt Historical Data

The historical data trend for Mereo BioPharma Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Long-Term Debt Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

7.05

22.00

19.41

4.39

Mereo BioPharma Group Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Debt	Get a 7-Day Free Trial												19.41	-	-	4.62	4.39

Mereo BioPharma Group (NAS:MREO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Mereo BioPharma Group Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.